Personalized medicine has been a booming area in clinical research for the past decade, in which the detailed information about the patient genotype and clinical conditions were collected and considered to optimize the therapy to prevent adverse reactions. However, the utility of commercially available personalized medicine has not yet been maximized due to the lack of a structured protocol for implementation. In this narrative review, we explain the role of pharmacogenetics in personalized medicine, nextgeneration personalized medicine, i.e., patient-centric personalized medicine, in which the patient's comfort is considered along with pharmacogenomics to be a primary factor. We extensively discuss the classifications, strategies, tools, and drug delivery systems that can support the implementation of patient-centric personalized medicine from an industrial perspective.
Introduction
Archibald Garrod was the first to connect disease susceptibility and genetic inheritance. In 1956, the genetic basis behind the selective toxicity of primaquine was discovered. Identification of the role of cytochrome P450 (CYP450) enzymes in drug metabolism led to recognize the influence of varying levels of these enzymes in drug doses determination. After the success of the human genome project in 2003 the real drive toward personalized medicine commenced. Currently, the entire spectrum of molecular medicine, such as proteomics, metabolomics, and epigenomics, exhilarates the real establishment of personalized medicine [1] . According to Concert Genetics, 65,000 genetic testing products are available on the market with an approximate introduction of 10 new products each day. Genetic polymorphisms coequally impact the science of drug discovery, clinical trials, and dose fixing in therapies [2] . Delivering optimal therapy minimizes trial and error prescribing, thereby avoiding the occurrence of adverse drug reactions (ADRs). This strategy of personalized medicine demands a revolutionary change from the process of drug discovery to the determination of patients who will receive the therapy. However, to date, only a few drug candidates have been successful as personalized medicines, and the remaining drugs have been underutilized due to multiple issues, such as cost, lack of technology, and marketability. To overcome these issues, personalized medicine should transition into patient-centric personalized medicine, where the drug delivery systems and tools are customized for delivering the exact quantity of the drug needed by the patient in a comfortable way, thereby reducing adverse effects and enhancing treatment adherence. By streamlining the technology toward designing patient-centric formulations, the utilization of available drug candidates can be maximized. This review addresses the emphasized need for phase transfer, from general gene-based personalized medicine to patient-centric personalized medicine with the support of modern pharmaceuticals for the benefit of patients.
Current clinical practices
Decades of experience-based medical practice, where the physician makes a clinical decision that is reliant on his previous experience in similar types of patients, have been overruled by evidence-based medicine (EBM). The practice of EBM concentrates on epistemology or considers the evidence derived from clinical studies to advise a therapy. EBM considers various clinical research, such as evidence from (i) meta-analyses of randomized controlled research (RCR), (ii) comparative or case studies, and (iii) experts and clinical practices. The physician's decision on therapy follows screening of critical disease states along with patient education supported by this evidence [3] . EBM not only considers clinical research but also incorporates patientrelated factors for framing treatment guidelines, and the success rate depends only on the quality of the evidence [4] . From 2000 to 2015, the percentages of ADRs reported in developed and developing countries were 6.3% and 5.5%, respectively, in the adult population. Among these ADRs, 71 .7% in developed countries and 59.6% in developing countries were preventable [5] . To prevent these ADRs and to ensure complete and appropriate use of available drug candidates with the greatest therapeutic impact, it is necessary to focus on the pitfalls of EBM and to discover options for developing new strategies for medications.
Pitfall of EBM and reasons for choosing personalized medication
EBM prioritizes the clinical data derived from a group of people or a particular category of people in the final decision for therapy. The RCTs exclude most patients who will be consuming the drug once it gets approval from regulatory agencies. The internal validity of an RCT relates to the similarity of the test volunteers and the context targeted by the drug discovery process. The literature indicates that 95% of the targeted population is excluded from the study of asthma medications. In addition, the physical, psychological, and social well being of the patient is not considered during study assessments [6] . The drug discovery process gives more focus on a safe and effective dose rather than the best dose for the population. The number of variable doses is limited, and the population is homogenized based on inclusion criteria during clinical trials. For example, cancer patients at an age greater than 65 years who are already administered some drugs that may produce potential drug interactions, significant organ dysfunction, concurrent or prior malignancies, and comorbidities are excluded from clinical studies [7] . Considering the baseline features for the volunteers is a strategy of deleting variable responses supposed to be expressed during the trial. This strategy leads to serious adverse reactions once the drug is marketed into a large population. Nevertheless, the first and foremost question to be answered is "what is the possible outcome when the drug is given to a specific individual?" which is not answered by RCTs [8] . The reliability of the current best evidence in clinical decision making is an inevitable factor in EBM. Recent investigations revealed 1.97% of researchers commit fraudulent research, 14.2% of scientists identify fraudulent research behavior in colleges, and 5% of authors claimed their awareness in misrepresented data of clinical trials in which they have participated [9] . Clinical trial research is questionable when the funding source itself is the beneficiary. Independent trials are superior to the trials funded and designed by pharmaceutical companies [10] . In addition, most of the regulatory approved drugs that are available on the market have passed through clinical trials without considering pharmacogenetic parameters. These presented pitfalls of EBM address the need for modifications in the patient care approach.
Emergence of personalized medicine
The concept of individualization of pharmacotherapy gained more attention after the human genome project [11] . Further, the Haplotype map (HapMap) project, the largest human genetic variation study to date, described the patterns of variations in the human genome that have a role in the health and disease of an individual [12] . The genetic code differs from individual to individual up to 10 million points, which are called single nucleotide polymorphisms (SNPs). Despite these SNPs, human beings differ from one another by up to 0.1%, and this difference is sufficient to say that no two humans are genetically identical, even in the case of identical twins [13] . The evidence from these studies acknowledges the individualized attention necessity in therapy, resulting in the emergence of personalized medicine. Pharmacogenetics and pharmacogenomics appeared as branches explaining the genetic variation responsible for differences in drug action and widening the concept of "one drug fits all" to the right drug, the right patient at the right dose and the right time. Later, proteomics, transcriptomics, and metabolomics also secured their roles in personalized therapy. Personalized medicine does not mean that each patient is treated separately but that the treatment is given to a group of people characterized based on genetic and other markers that predict disease progression and treatment outcome. The concept of personalized medicine offers benefits of reducing toxic effects and adverse events, thereby increasing the risk/benefit ratio of the drug [14] . The utilization of genetic information in personalized medicine can be broadly classified into two categories: pharmacogenetics in diagnosis and preventive care and pharmacogenetics in dose titration.
Pharmacogenetics in diagnosis and preventive care
It is not necessary that the same epigenetic or genomic variation exists in a specific phenotype (disease) in a different individual. The causal genes may vary among individuals even for the same disease. The drug response also varies according to the genetic features of an individual, disease heterogeneity, lifestyle, and environmental factors. Human leukocyte antigen (HLA) is the most polymorphic gene in the human genome. Individuals with the HLA-DQA1*0501, DQB1*0201 genotype are associated with chances of developing coeliac disease 200 times more than that of a normal individual. A common sequence pattern of HLA-DRB1 alleles indicates the risk factor for rheumatoid arthritis. Studying cytokine polymorphisms helps to predict the susceptibility and prognosis of a number of diseases, including types of cancers [15] . Only 10-30% of the patients with the same cancer respond in the same way to a particular drug. Breast cancer is classified into subtypes based on biomarkers such as oestrogen receptors, progesterone receptors, Kiel 67 receptor (Ki-67), and human epidermal receptor 2 (HER2). Recent studies in breast cancer therapy suggests gene expression profiling for optimizing the drug choice in therapy, since a mutation at the 17th position of the AKT1gene was identified in patients with breast cancer. This AKT1 is a major component of the PI3K-AKT-mTOR pathway, inhibitors that can target this pathway may be more efficacious in preventing tumor progression [16] . Family of fibroblast growth factor receptor (FGFR) genes (FGFR1, FGFR2, FGFR3, and FGFR4) are expressed irregularly in gastric cancer, soft-tissue sarcoma, lung cancer, endometrial uterine cancer, urothelial carcinoma, cholangiocarcinoma, and breast cancer. Pharmacodynamic receptors such as platelet derived growth factor receptor alpha(PDGFRA), platelet derived growth factor receptor beta (PDGFRB), neurotrophic receptor tyrosine kinase 1,2, and 3 (NTRK1, NTRK2, and NTRK3), rearranged during transfection receptor (RET), mesenchymal-epithelial transition factor (MET), reactive oxygen species modulator receptor (ROS1), FGFR 1,2,3, and 4 (FGFR1, FGFR2, FGFR3, and FGFR4), epidermal growth factor receptor (EGFR), ephrin type A3,A5,A7 receptors (EPHA3, EPHA5, and EPHA7), anaplastic lymphoma kinase (ALK), colony stimulating factor 1 receptor (CSF1R), ephrin type B1 (EPHB1), erythroblastic oncogene B2, B3, and B4 (ERBB2, ERBB3, and ERBB4), vascular endothelial growth factor receptor 1 (VEGFR1), Fms-like tyrosine kinase 1 (FLT1), vascular endothelial growth factor receptors 3 and 2(VEGFR3 and VEGFR2), insulin-like growth factor 1 receptor (IGF1R), and kinase insert domain receptor will serve as the targets for cancer therapies, so they can also be considered for polymorphism-based genomic testing. A drug of choice for the therapy changes according to the expressed gene family. In cases of greater ALK expression, drugs such as alectinib, ceritinib, and crizotinib will be employed, and afatinib, erlotinib, gefitinib, and osimertinib will be employed in patients with EGFR mutations. Drugs for FGFR inhibition are under clinical trials include derazantinib, infigratinib and erdafitinib. FGFR inhibitors are further divided into FGFR1, FGFR2, FGFR3, FGFR4, and pan-FGFR due to the divergence existing among them and to minimize toxic and adverse reactions by specifying the therapy [17] . Modern science facilitates the use of multiple advanced analytical instruments that aid in the uncomplicated screening of genes that are explained in Table 1 , which in turn aids in diagnosing patients and in specifying the disease category to physicians for providing proper preventive care and treatment.
Pharmacogenetics in dose titration
There are four possible expected outcomes from a patient who begins taking a drug. In the first case, the patient experiences no clinical benefits, but intolerable adverse reactions occur. In the second case, clinical benefits exist, but the extent of adverse reactions prohibits the use of the drug in the patient. Neither clinical benefits nor adverse reactions occur in the third case. In the final case, favorable clinical response along with little or no adverse reactions in patient are considered for continuation of the therapy. Despite these tedious screenings, it was estimated by the World Health Organization (WHO) that medication-related harm costs~42 billion US dollars per annum [18] . Even in the case of advanced drugs, a favorable response is produced only in 30-70% of the population. This varying response rate is attributed to genetic polymorphisms that result in altered drug absorption, distribution, metabolism, excretion and also the pharmacodynamic targets that may lead to therapeutic failure. These properties of gene-related drug activity contribute to a poor risk/benefit ratio in diverse populations (inter-individual variability) and can be managed with the help of personalized medicine [19] . Currently, the only option available in implementing personalized medicine is dose adjustment, which can be done based on monographs, professional information, empirical dose fixing, dose fixing by applying pharmacogenomics and pharmacokinetic models [20] . Among these methods, the pharmacogenomic-based dose titration model is considered to be an important criterion in personalized medicine. For example, 5FU can be used to explain the benefits of genetically determined dosing in patients. The preferred mainstay therapy in various gastrointestinal cancers, including gastric, colon and rectal cancer, is 5-fluorouracil (5FU). The rate-limiting enzyme of 5FU involved in~80-85% of the drug inactivation process is dihydropyrimidine dehydrogenase (DPYD). Currently, there are 30 variations identified in the gene DPYD, which codes for DPYD. Genetic variations in DPYD may be a reason for the insufficient activity of DPYD. DPYD*2 A, a common mutation in DPYD, causes insufficient DPYD activity and 5FU toxicity in 2-3% of patients. In a study conducted in 2594 colorectal cancer patients treated with 5FU, grade 3 toxicity was observed, and the toxicity was higher in patients with DPYD*2 A, I560S, and D949V mutations. Twenty-two out of 25 (88%, odds ratio (OR) 15.21; P < 0.001) patients with the DPYD*2 A mutation and 22 out of 27 (81%, OR 9.10; P < 0.001) patients with the D949V mutation had significant grade 3 or higher toxicities. In another prospective study, 5 FU was administered to 2038 patients who were genotyped for DPYD*2 A. Twenty-two patients among this group carried at least one variant allele, and they were prescribed half the normal 5FU dose. This genotype-guided dosing reduced the rate of grade ≥3 toxicity from 73 to 28%, and drug-induced death was reduced to 0 from 10%. The results from this prospective study are just a micro-level application of genetic information toward dose titration [21] . Various other polymorphisms that influences the drug pharmacokinetic /dynamic profile are mentioned in Table 2 .
Patient-centric personalized medicine
Patient-centric personalized medicine considers all precise data of a patient from the genetic level in prognosis of the disease, selection of the drug, optimization of the dose, and determination of the dosage regimen. Rather than an individual, a population with similar genetic variations is selected for a particular therapy. The necessity for the concept of patient-centric personalized medicine arises when the drug product reaches the patient, in which the compliance and adherence of the patient become the primary aspects determining the outcome of the therapy. The patient perspectives, such as their preferences, lifestyles, beliefs, comfort, and barriers, change from one patient to another. These perspectives demand the development of multiple variant formulations in a selected and specific population to satisfy a single unique set of patient needs and to achieve a meaningful outcome for each individual patient [22] . For example, cancer patients are still waiting for targeted, controlled release, needle-free drug delivery, and targeted drug delivery systems that can simultaneously deliver more than one drug based on their genetic makeup and specific needs (https://ww2.frost.com/ frost-perspectives/preference-targeted-therapies-and-pa tient-centric-approaches-drive-transformations-oncologydrug-delivery-market/). Adding the patient perspective and novel drug delivery technology to personalized medicine to treat a targeted population with the maximum therapeutic success rate and improved patient compliance can be described as patient-centric personalized drug delivery.
Classification of the patient-centric personalized drug delivery system
Currently, the socioeconomic burden of disease is becoming a major consideration for drug development [23] . Therefore, it is necessary to seriously consider the cost and need for Capture and interrogation of cell-free tumor DNA.
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Affymetrix Company, Santa Clara patient-centric personalized medicine. Based on the cost and need-based inter-individual flexibility, patient-centric personalized medicine can be classified into four types [24] , as shown in Fig. 1 .
Class I
High inter-individual variability, in terms of both the genetics and acceptability level of the patient that results in prevalent therapeutic failure, ADR incidence, and lack of adherence. However, under the patient-centric personalized platform, these incidences can be nullified; thus, these treatments will be cost effective. Certain drugs, such as warfarin and clopidogrel, are in this category [25, 26] .
Class II
There are no special provisions in clinical trials stating that the safety index of new drug candidates should be established only after screening the genetic polymorphism-based inter-individual variability [27] . Molecules under these categories are new, generally protected by intellectual property rights and exempt from price control agencies.
Therefore, drugs in this class show high inter-individual variability, and we cannot expect cost-effective patientcentric personalized medicine. Example: most of the patented drugs, such as lenalidomide.
Class III
This class includes multivitamin/multimineral supplements, which generally prove to have a high safety index and prophylactic action. Therefore, we can state that this category consists of medicaments with low inter-individual variability but on developing nutrigenomic-based patientcentric personalization significantly improves the intended outcome with minimal cost [28] .
Class IV
Drugs with broad therapeutic index, low inter-individual variability and non-systemic action can be categorized under this category, in which it is not important to commission under patient-centric personalized category. Even if this class of drugs shifts toward patient-centric personalized medicine, it will result in higher cost therapy than the 
Strategies toward implementing patientcentric personalized medicine
Identifying individual therapeutic needs can rectify only half of the issues; however, in patient-centric personalized medicine, the challenge of the remaining 50% of the issues includes preparing a dosage form that should be therapeutically, psychologically and economically accepted by the patient. Thus, finding an easy method of customization is a second important task that can lead to new pathways for implementing personalized medicine [29] . Multi-directional research, including in vitro diagnostic devices and strategic formulations ranging from microneedles to a modified inkjet printer, were developed and upgraded to fulfill the desire to dispense flexible dosages of multiple medications for the convenience of the patient [30] .The implementation of patient-centric personalized medicine includes three components: in vitro companion diagnostics, customization technologies, and customizable dosage forms.
In vitro companion diagnostics
The increasing interest in patient-centric personalized medicine facilitate the parallel development of new pharmaceutical product along with companion diagnostic test or assay for an inherited disease detecting biomarker. These companion diagnostics (CDxs) are tests capable of identifying specific mutations and biomarkers that help in the elucidation of disease pathways and stratification of the population, targeting drug therapy, monitoring the drug response during the course of treatment, determining the effectiveness of the drug product, and determining a regulatory link during and after the approval of the product [31] . The preferred development pathway for CDx is a prospective biomarker strategy, which starts during early preclinical trials in conjunction with product development [32] . This co-development ideology reduces the cost of development, increases the rate of success, and accelerates the regulatory approval process. The first companion diagnostic test (HercepTest™, Dako, California) was approved in 1998 by the USFDA for the drug Herceptin (Roche/ Genentech) [33] . To date, 38 CDxs have been approved by the USFDA for 8 different indications and for 37 drugs. Since the companion diagnostic tests appear as a gatekeeper regarding the treatment decision, in Japan, CDxs are class III medical devices [34] . The risk associated with a CDx is equal to the risk associated with the corresponding drug product [35] . The process of CDx development with a therapeutic product is shown in Fig. 2 . USFDA-approved CDxs, manufacturers, indications and specified drugs are shown in Table 3 . The CDx global market reached nearly $4.4 billion in 2016 and is expected to reach $25.1 billion in 2022. The growth of the companion diagnostic market has been attributed by the increase in ADRs, demands, studies and awareness of personalized medicine. Even though CDxs are the major component in the accomplishment of personalized medicine, the development of CDxs and their applications has not satisfactorily progressed for current patient-centric personalized medicine scenarios [36] . The co-development process for companion diagnostics faces a number of challenges. Conflicts of interest and motivations of a diagnostic developer may not match with the requirements of the pharmaceutical company, costing the pharmaceutical company's time, revenue and resources. The regulatory requirements must be satisfied by the pharmaceutical product as well as the diagnostics [37] . There are more chances of failure in the diagnostics at the end stages of development that will cause a financial burden to the developer and hesitancy in sharing the financial by pharmaceutical companies. Current reimbursement strategies do not support the development of high efficacy devices since the sensitivity of the device requires an additional monetary investment. Integration of various major industrial partners leads to a better streamlined, lean, and robust companion diagnostic development model [38] . The approved CDx faces challenges in commercialization during its life cycle when regulatory, educational, and technological needs for commercialization remain unmet; thus, CDx can be considered a specified area of research to support growth of patient-centric personalized medicine (https://www.fda.gov/ medical-devices/vitro-diagnostics/list-cleared-or-approvedcompanion-diagnostic-devices-vitro-and-imaging-tools).
Customization technologies

3-dimensional printing (3DP)
The concept of 3DP was first introduced in the 20th century by Pierre A. L. Ciraud, who tried 3DP with multiple layers of powder material and simultaneous solidification with the help of high energy beams; in the 1980s, the first patent related to 3DP was filed. Sand binding and selective laser sintering (SLS) solidification technology of powders were developed by Ross Housholder and Carl Deckard, respectively. Then, this technology was upgraded into stereolithography (SLA) and implemented in a commercial market by Chuck Hull. In the 1980s and 1990s, Emanuel Sachs, an MIT scientist, and his co-workers patented "3DP Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery techniques" based on joining the selected regions of powder by binding the material, and this technique further paved the way toward its implementation in the field of pharmaceutical and biomedical sciences [39] . This technique is one of the most promising technologies that supports the production of customized patient-centric drug delivery materials, such as tablets and nanoparticles, and there are multiple 3D printing methods available, such as the printing-based inkjet systems, drop-on powder deposition, drop-on-drop deposition, nozzle-based deposition system, pressure-assisted micro syringes, fused deposition, and laser-based writing systems etc. [40] . In support of this technology, the USFDA also approved 3D drug products in 2015 [41] . The major drawbacks include multiple parameter optimizations, such as printing passes, speed, printing headline velocity, and space and time intervals between printing layers. The distance between the nozzle and powder layer should be considered to achieve a standard 3D-printed drug product. Along with this polymer selection, drying and clogging of the spray pore are also considered important drawbacks. Multiple researchers are working toward improving this technology to benefit society.
Hot melt extrusion technology (HMT)
The commercial utility of this technology was initiated around the1930s. Extrusion is a technical approach of channelizing the raw material into a finished product by passing through a die under controlled conditions. The specific advantage of this technology is that it can exhibit continuous production, not a batch process [42] . This device can be classified into two types based on the number of twinning screws as a single screw extruder and a twin-screw extruder; it can also be classified based on its process into dry and wet extrusions. The general extrusion process consists of major materials such as carriers, plasticizers, and extrusion aids such as chelating agents, antioxidants, and active pharmaceuticals. Initially, this technology was used by pharmaceutical companies to produce granules, pellets, and spheres. Later, on upgradation, this technology was supported in developing solid dispersed materials, specialized granules such as rapid release granules and sustained release granules, customized tablets, transdermal films, and implants [43] . Despite these advantages, the process of HMT carries certain serious disadvantages, including inability to process heat-sensitive materials such as protein molecules. Apart from these types of thermo labile molecules, other materials can be easily customized by this method, even on an industrial scale [44] . Multiple pharmaceutical studies have been conducted utilizing these two technologies for developing variable dosage forms for the social benefit, as shown in Table 4 .
Dosage form in customization
Drug delivery devices
In 2012, a re-engineered orthopaedic device was developed that can be customized based on the needs of the patient to provide both support and drug delivery action at the desired location for a specific orthopaedic injury condition; the research team has extensively worked on inorganic and non-ceramic coatings that can exhibit sustained drug release to heal the injury [45] . Micro-and nanofabrication technologies enable site-specific drug delivery by devices after they are surgically implanted at a particular site. The Alzet ® pump is an osmotically driven drug delivery device that is subcutaneously implanted and provides controlled drug delivery. The currently approved implantable devices on the market is iPrecio ® , which uses integrated electronics to program the drug regimen prior to implantation. Various other approved implantable devices are Chronogesic ® , ALZAmer ® , SABER™ Delivery System, Atrigel ® , Synchromed ® , Codman ® 3000, and Gliadel ® , a wafer deposit system [46] . Micro actuation implantable devices can be powered and controlled remotely by transcutaneous transformers and were designed for patients who required multiple injections a day over a long period of time [47] . Another device, a shape memory polymer actuator, was designed with a wireless resonant heater and works when the field frequency matches the resonance frequency [48] . MicroCHIPS™ developed drug reservoir array chips for a pulsatile drug delivery through a wireless electronic technique that delivers parathyroid hormone segments for patients with osteoporosis. Controlled analgesic pumps allow the drug dose to be tailored to the requirements of the patient. Electro-active controlled release films can be remotely controlled by the application of an electrical potential to deliver adrug. Scientists developed an implantable capsule containing insulin-producing cells that is controlled remotely and secretes insulin when the blood sugar level is high. This capsule was designed as a remote smart phone app-controlled device to replace insulin injection [49] . All these advanced drug delivery technologies support the customized patient-centric medication approach.
Drug delivery formulations
Customization can be performed by 3DP or HMT technology, but the delivery mode is inevitably an important segment in patient-centric personalized medicine to improve their adherence. Various patient groups in a patient-centric personalized medicine strategy require personalized dosage forms or modes of delivery during therapy. Children and elderly are two disparate groups that Melanotan-i Biodegradable Implants poly(D,L lactide-co-glycolide) (PLGA) copolymer 1997 Bhardwaj et al. [106, 107] Chlorpheniramine Maleate [121] necessitate patient-centric personalized dosage forms. Children, from neonates to early or late child, experience rapid changes in physiological functions and metabolism. These changes demand dosage forms with flexible dose administration along with the thought of patient compliance. A range of dosage forms and devices have been developed for paediatric drug delivery, such as orodispersible tablets, oral dispensers coupled to baby bottles, pill swallowing cups, medicated dosing straws, sustained release suspensions, medicated spoons that form an oral pulp, oral soluble films, chewable soft gel capsules, and easy-to-open capsules that are currently available on the market. Electronic minitablet dispensers, segmented easyto-score tablets, gel-forming easy-to-swallow oral films, multiple scored tablets, solid dosage pen devices, milkbased oral liquid formulations, and nipple shield drug delivery devices, are non-commercialized technologies in the field. Fast dissolving, fast dispersing, or fast melting tablets that were available in the market (WOWTAB ® , ORASOLV ® , EPDAS ® , FLASHTAB ® , FROSTA ® , ZYDIS ® , LYOC ® , QUICKSOLV ® , FLASHDOSE ® , etc.) provided an acceptable drug delivery system for elderly as well as children who have problems in swallowing tablets [50] . Modified-release formulations can improve patient compliance in cases of drugs with short half-life that require frequent administration. Hydrocodone bitartrate extendedrelease tablets CII (Hysingla™ ER) is an FDA-approved opioid analgesic formulated with abuse-deterrent properties and is prescribed for once-daily dosing [51] . Normalizing dose flexibility is one of the most important criteria in patient-centric personalized medicine. Liquid dosage forms are adapted with dose-splitting devices such as dropping pipettes, cups, spoons, syringes, and dropping tubes/bottles. Solid dosage forms, particularly tablets, are still the most accepted dosage forms in patients. Scored tablets are one of the best options in individualized therapy. Scored tablets are designed in such a way to avoid the non-uniform dose division of conventional tablets and are accepted by the USFDA. A specific number or volume of solid particles, such as mini tablets, powders, granules or pellets, can be administered directly or by dispersing or dissolving them in a portable medium for patient-centric individualization. Drug-loaded buccal strips with graduation marks, impregnation of liquid API (active pharmaceutical ingredient) on a fast-dissolving film matrix provides a platform for extemporaneous drug dispensing. Solid dosage pens are drugloaded rods prepared by the extrusion method with a cutting aid facilitating the individualization of the dose [24] . Modular drug delivery approaches facilitate the delivery of a number of drugs in various regions of the body at different times by incorporating drugs in various matrixes and combining them. Pathophysiological conditions that stress multiple drug combinations can be delivered in patient- [136] centric aspects through this single dosage form [52] . Further delivering the drug to the specific organ, cell, receptor, or metabolic pathway at an optimum concentration based on the disease and person, with minimum or no ADR is equally important and can be achieved to a greater extent by utilizing nanotechnology. Various drug delivery formulations and devices utilized in commercial markets are mentioned in Table 5 .
Nanotechnology
Nanotechnology is defined as a science of nanoparticles ranging in size from 20 to 200 nm, and these particles play a vital role in modern pharmaceutical sciences to deliver a drug at the target site, thereby enhancing its action [53] . These nanodrug delivery systems include polymeric nanoparticles, dentrimers, metallic nanoparticles, polymeric micelles, and liposomes [54] . In 2006, a group of scientists worked on a ciprofloxacin liposomal formulation with multiple surfactant ratios, analysed all physical parameters and reported a change in dissolution profile based on the surfactant, and this research was projected toward a personalized approach for treating patients [55] . Later, in 2014, research on theranostics and personalized treatment were initiated, and products such as oxaliplatin carbon dots were developed with the integral property of delivering anticancer drugs with simultaneous tracking [56] . Then, in 2016, a team of researchers worked extensively on magnetic nanoparticles and produced a potential tool to deliver a drug at a specific targeted site for anticancer treatment, and they collected data related to multiple magnetic nanomaterials that were used in customized treatments [57] . Nanoparticlealbumin bound paclitaxel, due to its functionalization properties, binds to Glycop-60 (Gp60), secreted protein acidic and rich in cysteine receptors (SPARC), which are commonly over expressed on stromal fibroblasts in pancreatic ductal adenocarcinoma and thereby produces a targeted action toward specific cancer cells [58] . Bioengineered nanoparticles can release or deliver either single or multiple drugs according to a physiological response at a specific time to a targeted site. Nanovesicles are promising drug carriers that enable the delivery of nucleic acids, and they are of considerable interest in cancer therapy as they can replace a defective gene or silence the expression of an oncogene [59] . Even with this set of advantages, nanovesicles also have serious issues, such as over-usage of organic solvents and surfactants, processing charge, stability, and regulatory guidelines; thus, these disadvantages of nanoparticles still play a crucial role in restricting their entry into the commercial market [60] . However, utilizing this technology to a greater extent, patient-centric personalized medicine can be easily achieved.
Challenges in achieving patient-centric personalized medicine
Patient-centric personalized medicine is a chance to revolutionize the health care system but requires effort from innovators, entrepreneurs, policy makers, regulators, and payers. Advances in genome technology after the human genome project addressed an exponential decrease in sequencing costs by~16,000-fold. Advanced technologies, such as next-generation sequencing, measurement of chromatin accessibility and genome editing, enabled dynamic and detailed assessment of DNA, RNA, and proteins and enhanced the resolution of human diseases analysis. The success of these technologies relies on the quality and accuracy of the measurements. The ability to translate these genomic data to predict or represent a clinical description is challenging because of the high degree of variability in the measurements from clinical settings. Progression in patientcentric personalized medicine demands precision in measuring the phenotypic outcomes. Electronic health records in association with mobile health devices and digitalization are now offering phenotype refinement. The lack of technological support for the precise measure of cellular, subcellular and environmental characteristics and phenotypic complexities significantly influence the patient-centric personalization of medicine. Patient groupings and targeting therapies to a group remain complex until advanced molecular technology coupled with the existing clinical measures can ascertain its accessibility at the population level [61] . As a drug becomes precise, it demands the use of optimized technologies, even in a clinical trial, a technical model is required to ingest, integrate, standardize, and unify these data. Based on gathered information from reliable sources, a clinical trial is designed with infrastructure that facilitates data quality, data flow, trial logistics, data sharing, real-time data analysis, and modification of the trial according to new information. Genetic polymorphism-based groupings in clinical trials can also prevent the incidence of unpredictable ADRs; thus, the rate of rejection can be reduced. However, these clinical trials require rigorous discussions and understanding between sponsors, management groups, and regulatory authorities. Even though regulatory requirements are intended to establish the safety of a clinical trial, they have an impact on the cost of a patient-centric clinical trial, which in turn reflects on the cost of a product meant for a smaller population [62, 63] . Identification and validation of a biomarker is challenging and a lack of technically validated analytical assay methods restricts their application in a clinical setting. The development of this assay method should be balanced between the cost and regulatory requirements. Therefore, collaborative engagements among physicians, patients, and pharmaceutical companies are essential in achieving patient-centric personalized medicine. Understanding the perspective of stakeholders and establishing collaborations to share experiences, research outcomes, and policies will be helpful to health care delivery organizations to adopt the new therapeutic culture [64] , Combination of genomics and advanced drug delivery technology in the right proportion can create a path toward next-generation patient-centric personalized medicine in which patient will take medicine with confidence and comfort.
Future and industrial perspective of patientcentric personalized medicine ADR contributes to 6.7% of all hospitalizations and is the fourth major contributor to inpatient death in Western countries. ADRs challenge the health care system in terms of patient safety and medical expenses. From 1990 to 2012, 43 drugs were withdrawn from the market due to serious ADRs. In this manner, ADRs challenge the pharmaceutical sector. Personalized medicine approaches based on pharmacogenomics have large potential to avoid ADRs and improve the cost-effectiveness of health care; a new market intelligence by BIS reported that in 2016 the global precision medicine market accounted for $43.59 billion and predicted an 11.23% compound annual growth rate between 2017 and 2026 [65] . The number of personalized drugs with a specific biomarker increased from 5 in 2008 to 132 in 2016. In 2017, 30% of new drugs approved by the USFDA were personalized medicines, which included three gene therapies: one for B-cell lymphoma, one for retinal dystrophy, and one for lymphoblastic leukaemia. The first personalized biosimilar (infliximab) was also approved in 2017. Millions of individuals in the USA for whom the required drug dose is not available in a manufactured dosage form rely on specialized compounding pharmacies. These requirements and well-established successive track records of personalized medicine will justify the need for next-generation pharmaceutical industries that are skilled in patient-centric personalized medicine [66] .
Conclusion
Patient-centric personalized medicine brings back the days where apothecaries performed precise compounding of medications to help an individual patient. The successful dose titration based on the gene polymorphic biomarkers from the preclinical desk to a clinic can benefit real execution of personalized medicine. Along with the personalized medicine addition of smart drug delivery systems for enhancing patient comfort will enlighten the path toward transition of personalized medicine to patient-centric customized medicine. This strategy may not be cost effective at the initial stage, but in the long term, it can reduce the trial and error approach, reduce ADRs, and improve the comfort of patients in economical ways. Further studies on the introduction of new, cost effective, user friendly, software simulation-supported technologies for population grouping, genetic analysis, and adherable drug delivery systems allow for the extemporaneous change toward realistic commercialization of patient-centric personalized medicine, which can benefit both the population and drug developers.
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